Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 236,400 shares, a drop of 9.6% from the March 15th total of 261,500 shares. Based on an average daily volume of 88,300 shares, the days-to-cover ratio is presently 2.7 days.

Enlivex Therapeutics Trading Up 2.1 %

Shares of ENLV traded up $0.03 during mid-day trading on Wednesday, reaching $1.48. The company had a trading volume of 373,238 shares, compared to its average volume of 167,623. Enlivex Therapeutics has a twelve month low of $1.15 and a twelve month high of $4.59. The company’s 50-day moving average is $3.41 and its 200-day moving average is $2.55.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in shares of Enlivex Therapeutics during the first quarter valued at $68,000. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 89.6% in the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock valued at $294,000 after purchasing an additional 24,807 shares during the period. Bank of America Corp DE boosted its holdings in Enlivex Therapeutics by 87.0% during the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after buying an additional 2,867 shares during the last quarter. Finally, UBS Group AG grew its position in shares of Enlivex Therapeutics by 73.4% during the 3rd quarter. UBS Group AG now owns 31,871 shares of the company’s stock worth $136,000 after buying an additional 13,490 shares during the period. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their target price on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 12th.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.